**Supplement 2.** Two supplementary tables.

|  |
| --- |
| Supplementary Table 1*.* Patient and clinical characteristics by choice of anesthetic in the restricted propensity score (PS) matched cohort |
|   |
|   | **Restricted**  **PS matched cohort** |
|  | **Inhaled volatiles** | **Propofol** | **Standardized mean difference** |
|  | **n (%)** | **n (%)** |
| **Total number of subjects** |  4660 (100.0)  |  4660 (100.0)  |   |
| **Age at surgery, median (Inter Quartile Range)** |  67.0 (55.0-74.0) |  66.0 (57.0-73.3) | 0.025 |
| **Gender, female** |  - |  - |   |
| **ASA classification** |   |   | 0.028 |
| ASA 1 |  1204 (25.8)  |  1188 (25.5)  |   |
| ASA 2 |  2575 (55.3)  |  2633 (56.5)  |   |
| ASA 3-5 |  881 (18.9)  |  839 (18.0)  |   |
| **Local/regional anesthesia** |   |   |   |
| Regional block |  - |  - |   |
| Wound infiltration |  - |  - |   |
| **Year of surgery, median (Inter Quartile Range)** | 2017 (2016-2018) | 2017 (2016-2018) | 0.046 |
| **Surgery volume** |   |   | 0.052 |
| < 100 surgeries |  138 ( 3.0)  |  112 ( 2.4)  |   |
| 100-500 surgeries |  198 ( 4.2)  |  164 ( 3.5)  |   |
| 500+ surgeries |  4324 (92.8)  |  4384 (94.1)  |   |
| **Diagnosed at screening** |  2160 (46.4)  |  2371 (50.9)  | 0.091 |
| **Tumor/Metastasis/Node-staging** |   |   |   |
|  T1 |  - |  - |   |
|  T2 |  - |  - |   |
|  T3 |  - |  - |   |
|  T4 |  - |  - |   |
| **Node stage** |   |   |   |
|  N0 |  - |  - |   |
|  N1-N3 |  - |  - |   |
|  NX |  - |  - |   |
| **Metastasis stage** |   |   |   |
| M0 |  - |  - |   |
|  M1 |  - |  - |   |
|  MX |  - |  - |   |
| **Estrogen Receptor status** |   |   | 0.065 |
|  Postive |  3631 (77.9)  |  3739 (80.2)  |   |
|  Negative |  947 (20.3)  |  844 (18.1)  |   |
|  Not Performed |  32 ( 0.7)  |  39 ( 0.8)  |   |
|  Missing |  50 ( 1.1)  |  38 ( 0.8)  |   |
| **Progesteron Receptor status** |   |   |   |
|  Postive |  - |  - |   |
|  Negative |  - |  - |   |
|  Not Performed |  - |  - |   |
|  Missing |  - |  - |   |
| **Nuclear antigen, marker of proliferation status** |   |   | 0.061 |
|  Low |  2052 (44.0)  |  2190 (47.0)  |   |
|  Intermediate |  412 ( 8.8)  |  403 ( 8.6)  |   |
|  High |  1725 (37.0)  |  1636 (35.1)  |   |
|  Not Performed |  471 (10.1)  |  431 ( 9.2)  |   |
| **Human Epidermal growth factor Receptor 2 status** |   |   | 0.055 |
| 0-1+ |  2717 (58.3)  |  2827 (60.7)  |   |
| 2+ |  888 (19.1)  |  863 (18.5)  |   |
| 3+ |  312 ( 6.7)  |  269 ( 5.8)  |   |
| Not performed |  743 (15.9)  |  701 (15.0)  |   |
| **Adjuvant treatment** |   |   |   |
| Chemotherapy |  - |  - |   |
| Radiotherapy |  - |  - |   |
| Endocrine therapy |  - |  - |   |
| Antibodies |  - |  - |   |
| **Main reason for surgery** |   |   | 0.040 |
| Breast Conserving Therapy |  2902 (62.3)  |  2958 (63.5)  |   |
|  Mastectomy |  1310 (28.1)  |  1304 (28.0)  |   |
|  Modified radical mastectomy |  442 ( 9.5)  |  394 ( 8.5)  |   |
|  Surgery of relapses |  6 ( 0.1)  |  4 ( 0.1)  |   |
| **Post surgery treatment** |   |   |   |
| Chemotherapy |  - |  - |   |
| Radiotherapy |  - |  - |   |
| Endocrine therapy |  - |  - |   |
| Antibodies |  - |  - |   |
|   |   |   |   |

|  |
| --- |
| Supplementary Table 2. Three- and five-year overall survival and overall mortality expressed as Hazard Ratios (HR) with 95% CI by choice of anesthetic for the restricted PS matched cohort. |
|  |
|   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |  |
|   | **Three year survival** |  | **Five year survival** |   | **Overall mortality** |  |
|   | **Events** | **At risk** | **3 year** | **95% CI** | ***P*-value** |  | **Events** | **At risk** | **5 year** | **95% CI** | ***P*-value** |   | **HR** | **95% CI** |  |
| **Restricted**  **PS Matched** |  |  |   |   |   |   |   |   |   |   |   |   |   |   |  |
| Inhaled volatiles | 185 | 2158 | 91.4 | 90.4-92.3 | 0.496 |   | 57 | 451 | 87.3 | 85.8-88.8 | 0.642 |   | 1.00 | reference |  |
| Propofol | 175 | 2189 | 92.0 | 91.1-92.9 |   | 86 | 610 | 85.8 | 84.3-87.4 |   | 1.04 | 0.90-1.19 |  |
|  |  |  |   |   |   |   |   |   |   |   |   |   |   |   |  |